Bacil Pharma share news, announcements and annual reports
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹18.40.
30 Oct: open ₹18.50, high ₹18.99, low ₹18.40
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹27 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 1.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,126
Bacil Pharma share news and announcements
542 announcements, routine notices left out, newest first. Page 5 of 11.
Sep 2023
14 Sep · Management
14 Sep · Board meeting
Aug 2023
24 Aug · Meeting
7 Aug · Board meeting
Meeting on 14 Aug 2023: quarterly results
May 2023
20 May · Board meeting
16 May · Results
8 May · Board meeting
Meeting on 16 May 2023: audited results
Apr 2023
22 Apr · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Mar 2023
21 Mar · Board meeting
Meeting on 21 Mar 202321 Mar · Board meeting
Feb 2023
11 Feb · Board meeting
2 Feb · Board meeting
Meeting on 11 Feb 2023: quarterly results
Nov 2022
2 Nov · Board meeting
Oct 2022
25 Oct · Board meeting
Meeting on 2 Nov 2022: quarterly results1 Oct · Results
Sep 2022
7 Sep · Reg. 34 (1) Annual Report.
1 Sep · Meeting
Aug 2022
12 Aug · Results
3 Aug · Board meeting
Meeting on 12 Aug 2022: quarterly results
May 2022
30 May · Non-Applicability Regulation 23(9) Disclosure Related Party Transactions For The March Quarter And Year Ended, 2022